Skip to main content
IMRX
NASDAQ Life Sciences

Immuneering Extends Cash Runway to Q4 2028 as Phase 3 Enrollment Runs Ahead of Schedule

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.02
Mkt Cap
$260.084M
52W Low
$3.38
52W High
$8.48
52W Position info
19% above low
Off High info
53% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IMRX sits 19% above its 52-week low of $3.38.

Summary

Immuneering ended Q3 2026 with $166.1 million in cash and marketable securities, down from $217.0 million at year-end 2025, and now expects that to fund operations into Q4 2028. The runway extension reflects a longer Phase 2 pancreatic cancer follow-up — patients are living longer than projected, pushing updated atebimetinib + mGnP data (N=55) to 1H 2027 — plus an expanded Phase 3 MAPKeeper 301 enrollment target of roughly 570 patients, up from 510, which could pull the mid-2028 topline readout forward. The quarter's cost base rose sharply: R&D hit $20.7 million versus $10.9 million a year ago on higher clinical and personnel spend, and net loss widened to $24.2 million, or $0.37 per share, from $15.0 million. The clinical momentum is the story here — ahead-of-schedule enrollment and extended survival follow-up support the thesis, while the burn rate and the 1H 2027 data slip are the trade-offs. Next visible checkpoint is SITC in Q4 2026 with preclinical atebimetinib plus anti-PD-1 lung cancer data, alongside first patient dosing in that lung cancer Phase 2.

At the time of this announcement, IMRX was trading at $4.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.1M. The 52-week trading range was $3.38 to $8.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

IMRX - Latest Insights

IMRX
Oct 29, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.71 info
Change: -$0.310 (-8%) info
Market Cap: $240.271M info
IMRX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.36
Real-time Price: $3.71 info
Change: -$0.650 (-15%) info
Market Cap: $240.271M info
IMRX
Aug 05, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $3.71 info
Change: -$0.520 (-12%) info
Market Cap: $240.271M info
IMRX
Jul 21, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $3.71 info
Change: -$0.800 (-18%) info
Market Cap: $240.271M info
IMRX
Jun 15, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $3.71 info
Change: -$0.480 (-11%) info
Market Cap: $240.271M info